PL377040A1 - Sposób leczenia zawału mięśnia sercowego - Google Patents

Sposób leczenia zawału mięśnia sercowego

Info

Publication number
PL377040A1
PL377040A1 PL377040A PL37704003A PL377040A1 PL 377040 A1 PL377040 A1 PL 377040A1 PL 377040 A PL377040 A PL 377040A PL 37704003 A PL37704003 A PL 37704003A PL 377040 A1 PL377040 A1 PL 377040A1
Authority
PL
Poland
Prior art keywords
treatment
myocardial infarction
infarction
myocardial
Prior art date
Application number
PL377040A
Other languages
English (en)
Other versions
PL209912B1 (pl
Inventor
David A. Cheresh
Robert Paul
Brian Eliceiri
Original Assignee
The Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Scripps Research Institute filed Critical The Scripps Research Institute
Publication of PL377040A1 publication Critical patent/PL377040A1/pl
Publication of PL209912B1 publication Critical patent/PL209912B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A01K67/0271—Chimeric animals, e.g. comprising exogenous cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
PL377040A 2002-11-18 2003-11-18 Zastosowanie inhibitora kinazy tyrozynowej w medycynie PL209912B1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/298,377 US20030130209A1 (en) 1999-12-22 2002-11-18 Method of treatment of myocardial infarction

Publications (2)

Publication Number Publication Date
PL377040A1 true PL377040A1 (pl) 2006-01-23
PL209912B1 PL209912B1 (pl) 2011-11-30

Family

ID=32324361

Family Applications (1)

Application Number Title Priority Date Filing Date
PL377040A PL209912B1 (pl) 2002-11-18 2003-11-18 Zastosowanie inhibitora kinazy tyrozynowej w medycynie

Country Status (13)

Country Link
US (1) US20030130209A1 (pl)
EP (1) EP1567160A4 (pl)
JP (1) JP2006510620A (pl)
KR (1) KR101174333B1 (pl)
CN (1) CN100577170C (pl)
AU (1) AU2003293037A1 (pl)
BR (1) BR0316382A (pl)
CA (1) CA2506476C (pl)
MX (1) MXPA05005307A (pl)
PL (1) PL209912B1 (pl)
RU (1) RU2330665C2 (pl)
WO (1) WO2004045563A2 (pl)
ZA (1) ZA200504774B (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2041071E (pt) 2006-06-29 2014-09-23 Kinex Pharmaceuticals Llc Composições de biarilo e processos para a regulação de uma cascata de cinases
TWI457336B (zh) 2006-12-28 2014-10-21 Kinex Pharmaceuticals Llc 調節激酶級聯之組成物及方法
US8642067B2 (en) 2007-04-02 2014-02-04 Allergen, Inc. Methods and compositions for intraocular administration to treat ocular conditions
WO2009051848A1 (en) 2007-10-20 2009-04-23 Kinex Pharmaceuticals, Llc Pharmaceutical compositions for modulating a kinase cascade and methods of use thereof
WO2009142679A2 (en) * 2008-03-26 2009-11-26 Orthologic Corp. Methods for treating acute myocardial infarction
EP2905024A1 (en) * 2014-02-07 2015-08-12 Institut Quimic De Sarriá Cets, Fundació Privada Pyrido[2,3-d]pyrimidine-7(8H)-one derivatives for the treatment of infections caused by Flaviviridae
EP3569249A4 (en) * 2016-12-27 2020-11-11 Osaka University MEDICAL COMPOSITION FOR TREATMENT OF CONTINUOUS HEART DISEASE
CN113209096B (zh) * 2021-05-17 2022-06-14 武汉大学 培西达替尼在制备预防、缓解和/或治疗心肌梗死及其相关疾病药物中的应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5731343A (en) * 1995-02-24 1998-03-24 The Scripps Research Institute Method of use of radicicol for treatment of immunopathological disorders
US5593997A (en) * 1995-05-23 1997-01-14 Pfizer Inc. 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors
AU4753697A (en) 1996-10-01 1998-04-24 South Alabama Medical Science Foundation Method for diminishing myocardial infarction using protein phosphatase inhibitors
US7863444B2 (en) * 1997-03-19 2011-01-04 Abbott Laboratories 4-aminopyrrolopyrimidines as kinase inhibitors
US6235740B1 (en) * 1997-08-25 2001-05-22 Bristol-Myers Squibb Co. Imidazoquinoxaline protein tyrosine kinase inhibitors
IL135176A0 (en) * 1997-11-10 2001-05-20 Bristol Myers Squibb Co Benzothiazole derivatives and pharmaceutical compositions containing the same
DE69943374D1 (de) * 1998-05-29 2011-06-01 Us Government Verfahren zur modulation der angiogenese mittels der tyrosin kinase src
TR200101395T2 (tr) * 1998-09-18 2001-11-21 Basf Ag. Kinaz engelleyiciler olarak 4-Aminopyrrolopyrimidin'ler
US6921763B2 (en) * 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
EP1250155B1 (en) 1999-12-22 2008-04-16 The Scripps Research Institute Angiogenesis and vascular permeability modulators and inhibitors
US6521618B2 (en) 2000-03-28 2003-02-18 Wyeth 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors
SE518028C2 (sv) 2000-04-17 2002-08-20 Ericsson Telefon Ab L M Förfarande och metod för att undvika överbelastning i ett cellulärt radiosystem med makrodiversitet
JP2005500261A (ja) * 2001-04-10 2005-01-06 バーテックス　ファーマシューティカルズ　インコーポレイテッド Ｓｒｃおよび他のプロテインキナーゼのインヒビターとしてのイソキサゾール誘導体
IL159735A0 (en) * 2001-07-09 2004-06-20 Aventis Pharma Inc Substituted amides, sulfonamides and ureas useful for inhibiting kinase activity
US20060167021A1 (en) * 2002-10-04 2006-07-27 Caritas St. Elizabeth's Medical Center Of Boston, Inc. Inhibition of src for treatment of reperfusion injury related to revascularization

Also Published As

Publication number Publication date
KR20050086698A (ko) 2005-08-30
AU2003293037A1 (en) 2004-06-15
BR0316382A (pt) 2005-10-04
JP2006510620A (ja) 2006-03-30
CN100577170C (zh) 2010-01-06
KR101174333B1 (ko) 2012-08-16
CN1738624A (zh) 2006-02-22
CA2506476C (en) 2011-09-27
EP1567160A2 (en) 2005-08-31
WO2004045563A3 (en) 2004-12-23
WO2004045563A2 (en) 2004-06-03
PL209912B1 (pl) 2011-11-30
CA2506476A1 (en) 2004-06-03
MXPA05005307A (es) 2005-08-16
US20030130209A1 (en) 2003-07-10
EP1567160A4 (en) 2009-06-10
RU2005119174A (ru) 2006-01-20
RU2330665C2 (ru) 2008-08-10
ZA200504774B (en) 2006-03-29

Similar Documents

Publication Publication Date Title
IL164266A0 (en) Treatment of gastroparesis
HK1074784A1 (en) Treatment of mucositis
EP1577280A4 (en) DEUTERATION PROCESS
EP1626718A4 (en) METHOD FOR THE TREATMENT OF ISCHEMIC ILLNESSES
AU2003221195A8 (en) Method of diagnosing risk of myocardial infarction
EP1579010A4 (en) SUSCEPTIBILITY GENE FOR MYOCARDIAL INFARCTION AND METHODS OF TREATMENT
PL377040A1 (pl) Sposób leczenia zawału mięśnia sercowego
EP1488046A4 (en) CONSTRUCTION METHODS
GB0306309D0 (en) Method of treatment
AU2003262911A8 (en) Methods of promoting osteogenesis
GB0302572D0 (en) Method of treatment
GB0202906D0 (en) Prevention of myocardial damage
EP1553965A4 (en) TUMOR TREATMENT METHOD
GB0217493D0 (en) Novel methods of treatment
GB0208897D0 (en) New method of treatment
GB0221712D0 (en) Methods of treatment
AU2003252188A8 (en) Method of ore treatment
GB0213198D0 (en) Method of treatment
GB0222338D0 (en) Surface treatment of concrete
GB0301600D0 (en) Identification of risk of myocardial infarction
GB0327975D0 (en) Methods of treatment
GB0207091D0 (en) Method of treatment
GB0329357D0 (en) Treatment of materials
GB0304021D0 (en) Treatment of hypertension
GB0217492D0 (en) Novel method of treatment